Distress tolerance levels in alopecia areata patients

Aim: Alopecia areata (AA) is a clinical manifestation that is characterized with hair loss with hairs in sharp borders, and in a round or oval shape on the scalp or in any part of the body. It is considered that genetic factors, infections, autoimmune factors, neuropeptides and psychological factors play roles in its etiopathogenesis. As psychological traumas have an important role in the onset and exacerbation period of the disease, it is also considered as a psychosomatic one. Distress Tolerance (DT) is defined as the capacity to experience and survive negative psychological situations. DT is considered important in etiopathogenesis of diseases, and it is also considered as one of the factors that determine the response to treatment and is targeted to increase in psychotherapy. In the present study, the purpose was to determine the Distress Tolerance levels of AA patients, and compare them with healthy controls.Material and Methods: A total of 36 patients, who applied to the dermatology clinic, and who did not have any other diseases except AA, were included in the study. In the Control Group, 36 healthy volunteers, who were matched in terms of age and gender with the Patient Group, and who did not have any physical or mental illness, were included. The Sociodemographic and Clinical Data Form (SCDF), Distress Tolerance Scale (DTS), and Hospital Anxiety and Depression Scale (HADS) were given to the Patient and Control Group.Results: No significant differences were detected between the groups in terms of age and gender. A significant difference was detected in the Patient Group in terms of both the total score of DTS (p

PDF

___

1. Arca E, Kurumlu Z. Alopesi areatada etyopatogenez, klinik ve tanı. Dermatose 2003;2:83-9.
2. Garcia-Hernandez MJ, Ruiz-Doblado S, Rodriguez- Pichardo A, Camacho F. Alopecia areata, stress and psychiatric disorders: a review. J Dermatol 1999;26:625-32.
3. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol 2000;42:549-66.
4. Folks DG, Kinney FC. The role of psychological factors in dermatolologic conditions. Psychosomatics 1992;33:45-54.
5. Mulinari-Brenner. Psychosomatic aspects of alopecia areata. Clin Dermatol 2018;36:709-13.
6. Baghestani S, Zare S, Seddigh SH. Severity of depression and anxiety in patients with alopecia areata in Bandar Abbas, Iran. Dermatol Reports 2015;7:6063.
7. Ghanizadeh A, Ayoobzadehshirazi A. A review of psychiatric disorders comorbidities in patients with alopecia areata. Int J Trichology 2014;6:2-4.
8. Simons JS, Gaher RM. The distress tolerance scale: Development and validation of a self-report measure. Motiv Emot 2005;29:83-102.
9. Brown RA, Lejuez CW, Kahler CW, et al. Distress tolerance and early smoking lapse. Clin Psychol Rev 2005;25:713-33.
10. Leyro TM, Zvolensky MJ, Bernstein A. Distress tolerance and psychopathological symptoms and disorders: A review of the empirical literature among adults. Psychol Bull 2010;136:576-600.
11. Zvolensky MJ, Bernstein A, Vujanovic AA. Distress Tolerance: Theory, Research, and Clinical Applications: Guilford Publications 2011;80-3.
12. Anestis MD, Selby EA, Fink EL, et al. Themultifaceted role of distress tolerance in dysregulated eating behaviors. Int J Eat Disord 2007;40:718-26.
13. Brown RA, Palm KM, Strong DR, et al. Distress tolerance treatment for early-lapse smokers: rationale, program description, and preliminary findings. Behav Modif 2008;32:302-32.
14. Buckner JD, Keough ME, Schmidt NB. Problematic alcohol and cannabis use among young adults: the roles of depression and discomfort and distress tolerance. Addict Behav 2007;32:1957-63.
15. Sargın AE, Özdel K, Utku Ç, et al. Distress Tolerance Scale: A Study of Reliability and Validity. JCBPR 2012;1:152-61.
16. Zigmond AS, Snaith PR. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361- 70.
17. Aydemir Ö, Güvenir T, Küey L. Hastane Anksiyete ve Depresyon Ölçeği Türkçe formunun geçerlilik ve Güvenilirliği. Türk Psikiyatri Derg 1997;8:280-7.
18. Lee S, Lee H, Lee CH, Lee WS. Comorbidities in alopecia areata: A systematic review and meta-analysis.J Am Acad Dermatol 2019;80:466-77.e16.
19. Lee S, Lee WS. Management of alopecia areata: updates and algorithmic approach. J Dermatol 2017;44:1199-211.
20. Manolache L, Benea V. Stress in patients with alopecia areata and vitiligo. J Eur Acad Dermatol Venereol 2007;21:921-8.
21. Schmitt JV, Riberio CF, Souza FH, et al. Hair loss perception and symptoms of depression in female outpatients attending a general dermatology clinic. An Bras Dermatol 2012;87:412-7.
22. Okhovat JP, Marks DH, Manatis-Lornell A, et al. Association Between Alopecia Areata, Anxiety, and Depression: A Systematic Review and Meta-analysis.J Am Acad Dermatol. 2019;0190-9622:30890.
23. Chu SY, Chen YJ, Tseng WC, al. Psychiatric comorbidities in patients with alopecia areata in Taiwan: a case-control study. Br J Dermatol 2012;166:525-31.
24. Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol 2015;24:397-403.
25. Keough ME, Riccardi CJ, Timpano KR, et al. Anxiety symptomatology: The association with distress tolerance and anxiety sensitivity. Behav Ther 2010;41:567-74.